Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. Issue 5 (September 2021)

• Record Type: Journal Article
• Authors: Ellingson, Benjamin M.; Wen, Patrick Y.; Cloughesy, Timothy F.
• Is Part Of: Cancer journal. Volume 27:Issue 5(2021)
• Page Start: 395
• Page End: 403
• Publication Date: 2021-09
• Subjects: Early-phase clinical trials -- high-grade gliomas -- molecular imaging -- RANO -- response assessment; Cancer -- Periodicals; 616.994005
• DOI: 10.1097/PPO.0000000000000543
• Languages: English
• ISSNs: 1528-9117

Abstract

Abstract: Several new therapeutic strategies have emerged over the past decades to address unmet clinical needs in high-grade gliomas, including targeted molecular agents and various forms of immunotherapy. Each of these strategies requires addressing fundamental questions, depending on the stage of drug development, including ensuring drug penetration into the brain, engagement of the drug with the desired target, biologic effects downstream from the target including metabolic and/or physiologic changes, and identifying evidence of clinical activity that could be expanded upon to increase the likelihood of a meaningful survival benefit. The current review article highlights these strategies and outlines how imaging technology can be used for therapeutic response evaluation in both targeted and immunotherapies in early phases of drug development in high-grade gliomas.